trials of i-o therapy in driver mutation nsclc
Published 5 years ago • 31 plays • Length 3:30Download video MP4
Download video MP3
Similar videos
-
3:21
driver mutation nsclc: combining targeted and i-o therapy
-
3:48
i-o as first-line therapy for driver-mutated nsclc
-
7:26
personal use of i-o therapy in advanced-stage nsclc
-
5:55
surgery options for nsclc & i-o therapy in egfr-mutations
-
4:07
chemotherapy with i-o therapy in egfr- or alk-mutated nsclc
-
5:29
the role of driver mutations in nsclc treatment - 2022 program: lcvl
-
6:04
the future of driver mutations in nsclc
-
8:14
approaching non-driver stage iv nsclc
-
4:09
impact of driver mutations in nsclc
-
5:47
impower150: combining vegf and i-o therapy in nsclc
-
4:23
evolution of targeted therapy in advanced nsclc
-
2:20
selecting patients with nsclc who benefit from immunotherapy or targeted therapies
-
6:00
immunotherapy for patients with driver mutation - lung cancer video library
-
16:35
heterogeneity of nsclc and precipitating oncogenic driver mutations
-
16:03
grace targeted therapies lung cancer 2021 -the role of chemotherapy in driver positive patients
-
5:53
targeted therapy in non-small cell lung cancer
-
5:59
targeted therapy in consolidation setting for lung cancer
-
3:04
final thoughts on targeted therapy and i/o agents in nsclc
-
3:47
case 1: i-o therapy & autoimmune conditions in nsclc